What Are Emerging Treatments for Antisynthetase Syndrome?

When established treatments for antisynthetase syndrome (ASyS) do not adequately control symptoms or disease progression, patients and their care teams often look for other options. In rheumatology, disease that continues to be active despite a thorough trial of standard immunosuppressive medications is called refractory.

Currently, there are no targeted treatments officially approved by regulatory agencies specifically for ASyS. However, researchers are investigating several emerging therapies, including targeted biologic drugs and advanced cellular therapies. These are sometimes used off-label (using a drug approved for a different condition) or accessed through clinical trials. Because these therapies heavily suppress or alter the immune system, they carry significant risks and require careful evaluation by a specialist. You should never stop or change your current immunosuppressive medications without medical advice, as doing so can cause dangerous disease flares, particularly in the lungs.

Targeted Therapies (Biologics and Small Molecules)

JAK Inhibitors

JAK inhibitors (such as tofacitinib, baricitinib, and upadacitinib) are oral medications that block specific inflammatory pathways inside cells. They are approved for certain other autoimmune diseases but are considered investigational or off-label for ASyS.

In small, retrospective (backward-looking) case reports and uncontrolled series, JAK inhibitors have been associated with improvements in muscle symptoms, interstitial lung disease (ILD), and the ability to reduce steroid doses ^[1][2][3]. For example, in one retrospective review of 20 patients with refractory ASyS and ILD, 70% were reported to have clinical improvement, though the lack of a control group means it cannot be definitively proven that the drug caused the improvement ^[1].

JAK inhibitors carry important safety warnings. Risks include serious bacterial and viral infections (such as shingles and cytomegalovirus) ^[2][3]. Depending on the specific drug and individual patient risk factors, they can also increase the risk of blood clots (thrombosis), major cardiovascular events, certain cancers, and changes in blood counts, liver enzymes, and cholesterol levels. Treatment requires extensive specialist screening and ongoing laboratory monitoring.

IL-6 Inhibitors

Medications like tocilizumab and sarilumab block interleukin-6 (IL-6), an inflammatory protein. Case reports describing a small number of patients with severe ASyS have noted improvements in lung, muscle, and joint symptoms, along with a steroid-sparing effect ^[4][5].

However, individual case reports do not establish that a treatment is broadly effective. A broader clinical trial evaluating tocilizumab across various inflammatory myopathies did not meet its primary or secondary goals, meaning the true effectiveness of IL-6 inhibition for ASyS remains uncertain ^[6]. The risks of IL-6 inhibitors include increased vulnerability to infections, gastrointestinal perforation, and changes in liver tests and cholesterol. Additionally, these drugs can suppress fever and the inflammatory marker CRP, which can mask the early signs of new infections.

Abatacept

Abatacept, a biologic drug that alters T-cell activation, was evaluated in a small, 24-week pilot clinical trial for active ASyS-associated ILD ^[7]. The trial did not show a statistically significant difference between abatacept and a placebo in the primary lung function goal at 24 weeks ^[7]. Some later trends in the trial suggested potential benefits for lung function and shortness of breath, but these findings require larger studies to confirm ^[7]. Potential risks of abatacept include infusion reactions and increased susceptibility to respiratory and other infections.

Advanced Cellular Therapies

For highly refractory autoimmune diseases, researchers are exploring complex therapies traditionally used for blood cancers. These approaches generally target B cells (and related plasma cells). B-lineage cells contribute to autoimmunity and produce antibodies, though their exact pathogenic role in ASyS is still under investigation.

CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy involves collecting a patient’s own T cells, genetically modifying them in a laboratory to target a protein on B cells (such as CD19), and re-infusing them to deplete the patient’s B cells ^[8][9].

Early case reports and small “basket” studies (which group several autoimmune diseases together) have reported significant clinical responses in patients with inflammatory myopathies, with some patients even stopping other immunosuppressive drugs ^[8][10]. However, these are early, small-scale observations with short follow-up periods; it is not yet known how long any potential benefits might last, and drug-free remission is an exceptional early observation rather than a guaranteed outcome ^[10][9].

CAR-T is a highly intensive, investigational treatment that requires specialized centers, often involves preparatory chemotherapy, and carries severe, potentially life-threatening risks. These include Cytokine Release Syndrome (CRS) (a severe systemic inflammatory response) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) (which causes neurologic complications) ^[10][9]. Patients also face prolonged low white blood cell counts (cytopenias) and severely low antibody levels (hypogammaglobulinemia), which can lead to serious, long-term infection risks that may require regular intravenous immunoglobulin (IVIG) replacements ^[10][9].

T-Cell Engagers

T-cell engagers, such as blinatumomab (an approved drug for certain leukemias), are intravenous medications designed to force a patient’s T cells and B cells into close contact, causing the T cells to destroy the B cells ^[11].

In a small compassionate-use report involving five patients with treatment-refractory ASyS, blinatumomab was associated with rapid muscle improvement and stabilization of ILD ^[11]. Like CAR-T, this approach is highly experimental for ASyS and carries severe risks. Blinatumomab can cause CRS, severe neurotoxicity (ICANS), low blood counts, and serious respiratory infections ^[11].

Exploring Clinical Trials

Because ASyS is a rare disease, rigorous clinical trials are essential to determine which emerging therapies are truly safe and effective. If your condition is refractory, ask your care team about clinical trials. Participation usually requires care at a specialized academic medical center, strict medical screening, and a careful weighing of the unknown risks of experimental treatments against the potential benefits.